{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:28:22Z","timestamp":1770978502784,"version":"3.50.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40292-015-0082-7","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T09:43:39Z","timestamp":1425980619000},"page":"215-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension"],"prefix":"10.1007","volume":"22","author":[{"given":"Verdiana","family":"Ravarotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pagnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Fragasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo A.","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,11]]},"reference":[{"key":"82_CR1","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"92","author":"PK Mehta","year":"2007","unstructured":"Mehta PK, Griendling KK. Angiotensin II cell signaling. Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;92:C82\u201397.","journal-title":"Am J Physiol Cell Physiol"},{"key":"82_CR2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11906-011-0187-x","volume":"13","author":"A Nguyen Dinh Cat","year":"2011","unstructured":"Nguyen Dinh Cat A, Touyz RM. Cell signaling of angiotensin II on vascular tone: novel mechanisms. Curr Hypertens Rep. 2011;13:122\u20138.","journal-title":"Curr Hypertens Rep"},{"key":"82_CR3","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1172\/JCI26384","volume":"115","author":"VJ Dzau","year":"2005","unstructured":"Dzau VJ, Lopez-Ilasaca M. Searching for transcriptional regulators of Ang II induced vascular pathology. J Clin Invest. 2005;115:2319\u201322.","journal-title":"J Clin Invest"},{"key":"82_CR4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI36703","volume":"119","author":"A Benigni","year":"2009","unstructured":"Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009;119:524\u201330.","journal-title":"J Clin Invest"},{"key":"82_CR5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000188941","volume":"72","author":"L Cal\u00f2","year":"1996","unstructured":"Cal\u00f2 L, D\u2019Angelo A, Cantaro S, Rizzolo M, Favaro S, Antonello A, Borsatti A. Intracellular calcium signalling and vascular reactivity in Bartter\u2019s syndrome. Nephron. 1996;72:570\u20133.","journal-title":"Nephron"},{"key":"82_CR6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/HJH.0b013e328332b738","volume":"28","author":"LA Cal\u00f2","year":"2010","unstructured":"Cal\u00f2 LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D\u2019Angelo A, Pessina AC. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens. 2010;28:111\u20138.","journal-title":"J Hypertens"},{"key":"82_CR7","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/HJH.0000000000000321","volume":"32","author":"LA Cal\u00f2","year":"2014","unstructured":"Cal\u00f2 LA, Davis PA, Rossi GP. Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter\u2019s and Gitelman\u2019s syndromes, human models of endogenous angiotensin II signaling antagonism. J Hypertens. 2014;32:2109\u201319.","journal-title":"J Hypertens"},{"key":"82_CR8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0002-9343(62)90214-0","volume":"33","author":"FC Bartter","year":"1962","unstructured":"Bartter FC, Pronove P, Gill JR, Maccardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med. 1962;33:811\u201328.","journal-title":"Am J Med"},{"key":"82_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000076752","volume":"96","author":"M Naesens","year":"2004","unstructured":"Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter\u2019s and Gitelman\u2019s syndromes: From gene to clinic. Nephron Physiol. 2004;96:65\u201378.","journal-title":"Nephron Physiol"},{"key":"82_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ng0696-183","volume":"13","author":"DB Simon","year":"1996","unstructured":"Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter\u2019s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na\u2013K\u20132Cl cotransporter NKCC2. Nat Genet. 1996;13:183\u20138.","journal-title":"Nat Genet"},{"key":"82_CR11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ng1096-152","volume":"14","author":"DB Simon","year":"1996","unstructured":"Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP. Genetic heterogeneity of Bartter\u2019s syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet. 1996;14:152\u20136.","journal-title":"Nat Genet"},{"key":"82_CR12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng1097-171","volume":"17","author":"DB Simon","year":"1997","unstructured":"Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP. Mutation in the chloride channel gene CLCNKB cause Bartter\u2019s syndrome type III. Nat Genet. 1997;17:171\u20139.","journal-title":"Nat Genet"},{"key":"82_CR13","first-page":"221","volume":"79","author":"HJ Gitelman","year":"1966","unstructured":"Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Phys. 1966;79:221\u201335.","journal-title":"Trans Assoc Am Phys"},{"key":"82_CR14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1523-1755.2002.00467.x","volume":"62","author":"A Bettinelli","year":"2002","unstructured":"Bettinelli A, Tosetto C, Colussi G, Tommasini G, Edefonti A, Bianchetti MG. Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int. 2002;62:580\u20134.","journal-title":"Kidney Int"},{"key":"82_CR15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1365-2362.2008.02034.x","volume":"38","author":"R Scognamiglio","year":"2008","unstructured":"Scognamiglio R, Cal\u00f2 LA, Negut C, Coccato M, Mormino P, Pessina AC. Myocardial perfusion defects in Bartter and Gitelman syndromes. Eur J Clin Invest. 2008;38:888\u201395.","journal-title":"Eur J Clin Invest"},{"key":"82_CR16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.berh.2011.10.013","volume":"25","author":"M Favero","year":"2011","unstructured":"Favero M, Cal\u00f2 LA, Schiavon F, Punzi L. Bartter\u2019s and Gitelman\u2019s diseases. Best Pract Res Clin Rheumatol. 2011;25:637\u201348.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"82_CR17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1681\/ASN.2010090907","volume":"22","author":"R Vargas-Poussou","year":"2011","unstructured":"Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, Grisart B, Bridoux F, Unwin R, Moulin B, Haymann JP, Vantyghem MC, Rigothier C, Dussol B, Godin M, Nivet H, Dubourg L, Tack I, Gimenez-Roqueplo AP, Houillier P, Blanchard A, Devuyst O, Jeunemaitre X. Spectrum of mutation in Gitelman syndrome. J Am Soc Nephrol. 2011;22:693\u2013703.","journal-title":"J Am Soc Nephrol"},{"key":"82_CR18","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.peptides.2011.09.010","volume":"31","author":"A Nguyen Dinh Cat","year":"2011","unstructured":"Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system\u2014focusing on the vascular system. Peptides. 2011;31:2141\u201350.","journal-title":"Peptides"},{"key":"82_CR19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.yexcr.2012.02.023","volume":"318","author":"SD Crowley","year":"2012","unstructured":"Crowley SD, Coffman TM. Recent advances involving the renin-angiotensin system. Exp Cell Res. 2012;318:1049\u201356.","journal-title":"Exp Cell Res"},{"key":"82_CR20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0006-2952(97)00375-4","volume":"55","author":"E Clementi","year":"1998","unstructured":"Clementi E. Role of nitric oxide and its intracellular signalling pathways in the control of Ca2+ homeostasis. Biochem Pharmacol. 1998;55:713\u20138.","journal-title":"Biochem Pharmacol"},{"key":"82_CR21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","volume":"37","author":"VJ Dzau","year":"2001","unstructured":"Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension. 2001;37:1047\u201352.","journal-title":"Hypertension"},{"key":"82_CR22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0031-6997(24)01471-6","volume":"52","author":"RM Touyz","year":"2000","unstructured":"Touyz RM, Schiffrin EL. Signal transduction Mechanisms Mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639\u201372.","journal-title":"Pharmacol Rev"},{"key":"82_CR23","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1523-1755.2001.060003882.x","volume":"60","author":"LA Cal\u00f2","year":"2001","unstructured":"Cal\u00f2 LA, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, Davis PA, Costa R, Semplicini A. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int. 2001;60:882\u20139.","journal-title":"Kidney Int"},{"key":"82_CR24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1523-1755.2002.00128.x","volume":"61","author":"LA Cal\u00f2","year":"2002","unstructured":"Cal\u00f2 LA, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq-protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int. 2002;61:353\u20134.","journal-title":"Kidney Int"},{"key":"82_CR25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.ki.5000253","volume":"69","author":"LA Cal\u00f2","year":"2006","unstructured":"Cal\u00f2 LA. Vascular tone control in humans: insights from studies in Bartter\u2019s\/Gitelman\u2019s syndromes. Kidney Int. 2006;69:963\u20136.","journal-title":"Kidney Int"},{"key":"82_CR26","first-page":"12","volume":"51","author":"L Cal\u00f2","year":"1999","unstructured":"Cal\u00f2 L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, D\u2019Angelo A. Increased endothelial nitric oxide synthase mRNA level in Bartter\u2019s and Gitelman\u2019s syndrome. Relationship to vascular reactivity. Clin Nephrol. 1999;51:12\u20137.","journal-title":"Clin Nephrol"},{"key":"82_CR27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/000331979504601005","volume":"46","author":"L Cal\u00f2","year":"1995","unstructured":"Cal\u00f2 L, Cantaro S, Calabr\u00f2 A, Piarulli F, Rizzolo M, Favaro S, Antonello A, Crepaldi G, Borsatti A. Endothelium-derived vasoactive substances in Bartter\u2019s syndrome. Angiology. 1995;46:905\u201313.","journal-title":"Angiology"},{"key":"82_CR28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0272-6386(96)90514-4","volume":"27","author":"L Cal\u00f2","year":"1996","unstructured":"Cal\u00f2 L, D\u2019Angelo A, Cantaro S, Bordin MC, Favaro S, Antonello A, Borsatti A. Increased urinary NO2-\/NO3- and cyclic GMP levels in patients with Bartter\u2019s syndrome: relationship to vascular reactivity. Am J Kidney Dis. 1996;27:874\u20139.","journal-title":"Am J Kidney Dis"},{"key":"82_CR29","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1093\/ndt\/gfn118","volume":"23","author":"LA Cal\u00f2","year":"2008","unstructured":"Cal\u00f2 LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, Balbi G, Davis PA, Palatini P, Pauletto P. Absence of vascular remodelling in a high angiotensin-II state (Bartter\u2019s and Gitelman\u2019s syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant. 2008;23:2804\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"82_CR30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ndt\/gfg204","volume":"18","author":"LA Cal\u00f2","year":"2003","unstructured":"Cal\u00f2 LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter\u2019s and Gitelman\u2019s sindrome: relevance for angiotensin II signaling. Nephrol Dial Transplant. 2003;18:1518\u201325.","journal-title":"Nephrol Dial Transplant"},{"key":"82_CR31","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00004872-199816070-00014","volume":"16","author":"LA Cal\u00f2","year":"1998","unstructured":"Cal\u00f2 LA, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, Zambon S, Cantaro S, D\u2019Angelo A, Davis PA, Manzato E, Crepaldi G. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter\u2019s and Gitelman\u2019s sindrome). J Hypertens. 1998;16:1001\u20138.","journal-title":"J Hypertens"},{"key":"82_CR32","first-page":"pe2","volume":"370","author":"SP Heximer","year":"2007","unstructured":"Heximer SP, Blumer KJ. RGS proteins: Swiss army knives in seven-transmembrane domain receptor signaling networks. Sci STKE. 2007;370:pe2.","journal-title":"Sci STKE"},{"key":"82_CR33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0022-3565(24)29606-3","volume":"297","author":"H Zhong","year":"2001","unstructured":"Zhong H, Neubig RR. Regulator of G protein signalling proteins; novel multifunctional drug targets. J Pharmacol Exp Ther. 2001;297:837\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"82_CR34","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/nm958","volume":"9","author":"M Tang","year":"2003","unstructured":"Tang M, Wang G, Lu P, Karas RH, Karas RH, Aronovitz M, Heximer SP, Kaltenbronn KM, Blumer KJ, Siderovski DP, Zhu Y, Mendelsohn ME. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med. 2003;9:1506\u201312.","journal-title":"Nat Med"},{"key":"82_CR35","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1210\/jc.2004-0498","volume":"89","author":"LA Cal\u00f2","year":"2004","unstructured":"Cal\u00f2 LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, Semplicini A. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter\u2019s\/Gitelman\u2019s syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab. 2004;89:4153\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"82_CR36","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/01.hjh.0000226202.80689.8f","volume":"24","author":"A Semplicini","year":"2006","unstructured":"Semplicini A, Lenzini L, Sartori M, Papparella I, Cal\u00f2 LA, Pagnin E, Strapazzon G, Benna C, Costa R, Avogaro A, Ceolotto G, Pessina AC. Reduced expression of regulator of G protein signaling-2 in hypertensive patients increases calcium mobilization and ERK1\/2 phosphorylation induced by angiotensin II. J Hypertens. 2006;24:1115\u201324.","journal-title":"J Hypertens"},{"key":"82_CR37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/HJH.0b013e3282f60d98","volume":"26","author":"LA Cal\u00f2","year":"2008","unstructured":"Cal\u00f2 LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, Semplicini A, Pessina AC. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter\u2019s\/Gitelman\u2019s syndromes. J Hypertens. 2008;26:938\u201345.","journal-title":"J Hypertens"},{"key":"82_CR38","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1172\/JCI15598","volume":"111","author":"SP Heximer","year":"2003","unstructured":"Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos-Santos A, Penninger JM, Muslin AJ, Steinberg TH, Wyss JM, Mecham RP, Blumer KJ. Hypertension and prolonged vasoconstrictor signalling in RGS2-deficient mice. J Clin Invest. 2003;111:445\u201352.","journal-title":"J Clin Invest"},{"key":"82_CR39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11906-003-0073-2","volume":"5","author":"RM Touyz","year":"2003","unstructured":"Touyz RM. Role of Angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep. 2003;5:155\u201364.","journal-title":"Curr Hypertens Rep"},{"key":"82_CR40","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1161\/01.CIR.0000093661.90582.c4","volume":"108","author":"KK Griendling","year":"2003","unstructured":"Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part II. Animal and human studies. Circulation. 2003;108:2034\u201340.","journal-title":"Circulation"},{"key":"82_CR41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/01.RES.86.5.494","volume":"86","author":"KK Griendling","year":"2000","unstructured":"Griendling KK, Soresen D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res. 2000;86:494\u2013501.","journal-title":"Circ Res"},{"key":"82_CR42","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1097\/00004872-200410000-00019","volume":"22","author":"E Pagnin","year":"2004","unstructured":"Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Cal\u00f2 LA. Rho kinase and PAI-1 in Bartter\u2019s\/Gitelman\u2019s syndromes: relationship to angiotensin II signaling. J Hypertens. 2004;22:1963\u20139.","journal-title":"J Hypertens"},{"key":"82_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/HJH.0b013e328010d4d2","volume":"25","author":"LA Cal\u00f2","year":"2007","unstructured":"Cal\u00f2 LA, Pessina AC. RhoA\/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens. 2007;25:259\u201364.","journal-title":"J Hypertens"},{"key":"82_CR44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/01.RES.0000201960.04223.3c","volume":"98","author":"G Loirand","year":"2006","unstructured":"Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322\u201334.","journal-title":"Circ Res"},{"key":"82_CR45","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.ATV.0000176193.83629.c8","volume":"25","author":"H Shimokawa","year":"2005","unstructured":"Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25:1767\u201375.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"82_CR46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tips.2005.12.002","volume":"27","author":"K Budzyn","year":"2006","unstructured":"Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci. 2006;27:97\u2013104.","journal-title":"Trends Pharmacol Sci"},{"key":"82_CR47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/01.CIR.0000020682.73694.AB","volume":"106","author":"M Takemoto","year":"2002","unstructured":"Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002;106:57\u201362.","journal-title":"Circulation"},{"key":"82_CR48","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1074\/jbc.M212776200","volume":"278","author":"V Sauzeau","year":"2003","unstructured":"Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem. 2003;278:9472\u201380.","journal-title":"J Biol Chem"},{"key":"82_CR49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2006.08.038","volume":"408","author":"HG Jin","year":"2006","unstructured":"Jin HG, Yamashita H, Nagano Y, Fukuba H, Hiji M, Ohtsuki T, Takahashi T, Kohriyama T, Kaibuchi K, Matsumoto M. Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase\/ROCK2 inhibits eNOS expression. Neurosci Lett. 2006;408:62\u20137.","journal-title":"Neurosci Lett"},{"key":"82_CR50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11906-001-0028-4","volume":"3","author":"K Chitaley","year":"2001","unstructured":"Chitaley K, Weber D, Webb RC. RhoA\/Rho-kinase, vascular changes and hypertension. Curr Hypertens Rep. 2001;3:139\u201344.","journal-title":"Curr Hypertens Rep"},{"key":"82_CR51","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.RES.0000096650.91688.28","volume":"93","author":"M Higashi","year":"2003","unstructured":"Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-Kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767\u201375.","journal-title":"Circ Res"},{"key":"82_CR52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.HYP.35.1.313","volume":"35","author":"T Yamakawa","year":"2000","unstructured":"Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000;35:313\u20138.","journal-title":"Hypertension"},{"key":"82_CR53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/hy0202.103271","volume":"39","author":"C Kataoka","year":"2002","unstructured":"Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, Takeshita A. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 2002;39:245\u201350.","journal-title":"Hypertension"},{"key":"82_CR54","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/ndt\/gfl173","volume":"21","author":"E Pagnin","year":"2006","unstructured":"Pagnin E, Davis PA, Semplicini A, Cal\u00f2 LA. The search for a link between inflammation and hypertension\u2014contribution from Bartter\u2019s\/Gitelman\u2019s syndromes. Nephrol Dial Transplant. 2006;21:2340\u20132.","journal-title":"Nephrol Dial Transplant"},{"key":"82_CR55","doi-asserted-by":"crossref","first-page":"H1597","DOI":"10.1152\/ajpheart.00026.2004","volume":"286","author":"JR Sowers","year":"2004","unstructured":"Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597\u2013602.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"82_CR56","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/01.ATV.21.5.868","volume":"21","author":"K Takeda","year":"2001","unstructured":"Takeda K, Ichiki T, Tokunou T, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, Takeshita A. Critical role of Rhokinase and MEK-ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol. 2001;21:868\u201373.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"82_CR57","first-page":"H1744","volume":"278","author":"Y Eto","year":"2000","unstructured":"Eto Y, Shimokawa H, Hiroki J, Morishige K, Kandabashi T, Matsumoto Y, Amano M, Hoshijima M, Kaibuchi K, Takeshita A. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol. 2000;278:H1744\u201350.","journal-title":"Am J Physiol"},{"key":"82_CR58","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.ATV.0000183607.50230.9f","volume":"25","author":"T Nakakuki","year":"2005","unstructured":"Nakakuki T, Ito M, Iwasaki H, Kureishi Y, Okamoto R, Moriki N, Kongo M, Kato S, Yamada N, Isaka N, Nakano T. Rho\/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25:2088\u201393.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"82_CR59","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1161\/01.ATV.0000142813.33538.82","volume":"24","author":"S Wolfrum","year":"2004","unstructured":"Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, Liao JK. Inhibition of Rhokinase leads to rapid activation of phosphatidylinositol 3 kinase\/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004;24:1842\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"82_CR60","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1242\/jcs.01118","volume":"117","author":"K Wennerberg","year":"2004","unstructured":"Wennerberg K, Der CJ. Rho-family GTPases: it\u2019s not only Rac and Rho (and I like it). J Cell Sci. 2004;117:1301\u201312.","journal-title":"J Cell Sci"},{"key":"82_CR61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7150\/ijbs.1.51","volume":"1","author":"DP Siderovski","year":"2005","unstructured":"Siderovski DP, Willard FS. The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J Biol Sci. 2005;1:51\u201366.","journal-title":"Int J Biol Sci"},{"key":"82_CR62","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.amjhyper.2004.05.006","volume":"17","author":"Z Ying","year":"2004","unstructured":"Ying Z, Jin L, Dorrance AM, Webb RC. Increased expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2004;17:981\u20135.","journal-title":"Am J Hypertens"},{"key":"82_CR63","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1096\/fj.10-155499","volume":"24","author":"MC Wuertz","year":"2010","unstructured":"Wuertz MC, Lorincz A, Vettel C, Thomas MA, Wieland T, Lutz S. p63RhoGEF\u2014a key mediator of angiotensin II dependent signaling and processes in vascular smooth muscle cells. FASEB J. 2010;24:4865\u201376.","journal-title":"FASEB J"},{"key":"82_CR64","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCRESAHA.111.248898","volume":"109","author":"K Momotani","year":"2011","unstructured":"Momotani K, Artamonov MV, Utepbergenov D, Derewenda U, Derewenda ZS, Somlyo AV. p63RhoGEF couples Gaq\/11-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility. Circ Res. 2011;109:993\u20131002.","journal-title":"Circ Res"},{"key":"82_CR65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm.2079","volume":"16","author":"C Guilluy","year":"2010","unstructured":"Guilluy C, Br\u00e9geon J, Toumaniantz G, et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010;16:183\u201390.","journal-title":"Nat Med"},{"key":"82_CR66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/01.ATV.0000153089.74997.02","volume":"25","author":"LA Cal\u00f2","year":"2005","unstructured":"Cal\u00f2 LA, Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC. Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome. Arterioscler Thromb Vasc Biol. 2005;25:34\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"82_CR67","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/01.hjh.0000170394.99697.b3","volume":"23","author":"LA Cal\u00f2","year":"2005","unstructured":"Cal\u00f2 LA, Pagnin E, Sartori M, Semplicini A, Pessina AC. Bartter\u2019s and Gitelman\u2019s syndromes: a confirm in humans of the utility of Rho kinase inhibition for cardiovascular protection. J Hypertens. 2005;23:1273\u20135.","journal-title":"J Hypertens"},{"key":"82_CR68","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/HYPERTENSIONAHA.107.092296","volume":"50","author":"SR Datla","year":"2007","unstructured":"Datla SR, Dusting GJ, Mori TA, Taylor CJ, Croft KD, Jiang F. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension. 2007;50:636\u201342.","journal-title":"Hypertension"},{"key":"82_CR69","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1074\/jbc.M309660200","volume":"279","author":"D Martin","year":"2004","unstructured":"Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Cuadrado A. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase\/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem. 2004;279:8919\u201329.","journal-title":"J Biol Chem"},{"key":"82_CR70","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjhyper.2005.03.747","volume":"18","author":"E Pagnin","year":"2005","unstructured":"Pagnin E, Semplicini A, Sartori M, Pessina AC, Cal\u00f2 LA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter\u2019s and Gitelman\u2019s syndromes: relevance for the pathophysiology of hypertension. Am J Hypertens. 2005;18:1200\u20135.","journal-title":"Am J Hypertens"},{"key":"82_CR71","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/HJH.0000000000000075","volume":"32","author":"LA Cal\u00f2","year":"2014","unstructured":"Cal\u00f2 LA, Davis PA, Pagnin E, Dal Maso L, Maiolino G, Seccia TM, Pessina AC, Rossi GP. Increased level of p63RhoGEF and RhoA\/Rho kinase activity in hypertensive patients. Implications for vascular tone regulation and cardiovascular remodeling. J Hypertens. 2014;32:331\u20138.","journal-title":"J Hypertens"},{"key":"82_CR72","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.bbadis.2010.05.002","volume":"1802","author":"A Wirth","year":"2010","unstructured":"Wirth A. Rho kinase and hypertension. Biochim Biophys Acta. 2010;1802:1276\u201384.","journal-title":"Biochim Biophys Acta"},{"key":"82_CR73","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/01.hjh.0000166845.49850.39","volume":"23","author":"C Savoia","year":"2005","unstructured":"Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM. Negative regulation of RhoA\/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens. 2005;23:1037\u201345.","journal-title":"J Hypertens"},{"key":"82_CR74","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/BF03345754","volume":"32","author":"LA Cal\u00f2","year":"2009","unstructured":"Cal\u00f2 LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, Mormino P, Semplicini A, Palatini P, D\u2019Angelo A, Pessina AC. High angiotensin II state without cardiac remodeling (Bartter\u2019s and Gitelman\u2019s syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest. 2009;32:832\u20136.","journal-title":"J Endocrinol Invest"},{"key":"82_CR75","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.HYP.0000159192.93968.8f","volume":"45","author":"RM Carey","year":"2005","unstructured":"Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension. 2005;45:840\u20134.","journal-title":"Hypertension"},{"key":"82_CR76","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11906-008-0050-x","volume":"10","author":"HM Siragy","year":"2008","unstructured":"Siragy HM. Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Curr Hypertens Rep. 2008;10:261\u20137.","journal-title":"Curr Hypertens Rep"},{"key":"82_CR77","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/ndt\/gfl112","volume":"21","author":"PA Davis","year":"2006","unstructured":"Davis PA, Mussap M, Pagnin E, Bertipaglia L, Savica V, Semplicini A, Cal\u00f2 LA. Early markers of inflammation in a high angiotensin II state. Results of studies in Bartter\u2019s\/Gitelman\u2019s syndromes. Nephrol Dial Transplant. 2006;21:1697\u2013701.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl. 82","key":"82_CR78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1523-1755.62.s82.4.x","volume":"62","author":"M Ruiz-Ortega","year":"2002","unstructured":"Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int. 2002;62(Suppl. 82):12\u201322.","journal-title":"Kidney Int"},{"key":"82_CR79","first-page":"RA194","volume":"11","author":"ZJ Cheng","year":"2005","unstructured":"Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005;11:RA194\u2013205.","journal-title":"Med Sci Monit"},{"key":"82_CR80","first-page":"155","volume":"11","author":"UN Das","year":"2005","unstructured":"Das UN. Is angiotensin II an endogenous pro-inflammatory molecule? Med Sci Monit. 2005;11:155\u201362.","journal-title":"Med Sci Monit"},{"key":"82_CR81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1101\/gad.11.4.463","volume":"11","author":"R Perona","year":"1997","unstructured":"Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 1997;11:463\u201375.","journal-title":"Genes Dev"},{"key":"82_CR82","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0016-5085(03)00283-X","volume":"124","author":"JP Segain","year":"2003","unstructured":"Segain JP, Raingeard de la Bletiere D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P, Galmiche JP, Loirand G. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn\u2019s disease and experimental colitis. Gastroenterology. 2003;124:1180\u20137.","journal-title":"Gastroenterology"},{"key":"82_CR83","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/sj.jhh.1002309","volume":"22","author":"LA Cal\u00f2","year":"2008","unstructured":"Cal\u00f2 LA, Davis PA, Pagnin E, Schiavo S, Semplicini A, Pessina AC. Linking inflammation and hypertension in humans: studies in Bartter\u2019s\/Gitelman\u2019s syndromes. J Hum Hypertens. 2008;22:223\u20135.","journal-title":"J Hum Hypertens"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-015-0082-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40292-015-0082-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-015-0082-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T20:37:52Z","timestamp":1747773472000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40292-015-0082-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,11]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["82"],"URL":"https:\/\/doi.org\/10.1007\/s40292-015-0082-7","relation":{},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,11]]}}}